These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 589554)

  • 1. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract]   [Full Text] [Related]  

  • 5. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
    Presant CA; Klahr C
    Cancer; 1978 Sep; 42(3):1222-7. PubMed ID: 698913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
    Lee BJ; Sahakian G; Clarkson BD; Krakoff IH
    Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
    [No Abstract]   [Full Text] [Related]  

  • 7. Nitrosoureas in multiple myeloma.
    Salmon SE
    Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study.
    Alberts DS; Salmon SE
    Cancer Chemother Rep; 1975; 59(2 Pt 1):345-50. PubMed ID: 1097093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
    Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of myeloma maintenance regimen of prednisone. Adriamycin, imuran, and vincristine in a murine plasmacytoma model.
    Ghanta VK; Cohen HJ; Silberman HR; Durant JR; Hiramoto RN
    Cancer Clin Trials; 1981; 4(2):135-41. PubMed ID: 7249251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M; Amadori S; Cantonetti M; Franchi A; Papa G; Pileri A; Boccadoro M; Dammacco F; Vacca A; Centurioni R
    Leuk Res; 1985; 9(8):1043-9. PubMed ID: 3900591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
    Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].
    Bataille R; Morlock G; Rosenberg F; Sany J; Serre H
    Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.
    Kyle RA; Jacobus S; Friedenberg WR; Slabber CF; Rajkumar SV; Greipp PR
    Cancer; 2009 May; 115(10):2155-64. PubMed ID: 19248045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the status of the nitrosoureas in other tumors.
    Carter SK
    Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
    Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.